Treg engineers take aim at autoimmunity
Elie Dolgin • November 9, 2021
Companies are deploying regulatory T cells, equipped with CAR and TCR constructs, to suppress immunity — locally and for the long term.
Engineered adoptive T-cell therapies have already transformed the treatment of blood cancers. Now, several startups hope to harness the power of regulatory T cells (Tregs) to suppress immune responses and offer tolerance to transplant recipients, or to control the inflammation driving autoimmune disorders.
Continue reading at Nature Biotechnology.
With a call of 130 decibels, the bare-throated bellbird is a big-beaked marvel.
Autonomous blood-drawing devices could help address phlebotomist shortages.